1-3 of 3
Johanna Thomas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Single-Center Experience of Decitabine/Venetoclax in Newly Diagnosed Older AML Patients with Non-Favorable Genetics: Bridging to Allo-HCT or Treatment Continuation

David Alber, Christoph Rummelt, Tim Strüßmann, Andrés Rettig, Valeria Shlyakhto, Paul La Rosée, Martin Henkes, Elizaveta Bubnova, Tobias Ma, Johanna Thomas, Gabriele Ihorst, Claudia Wehr, Reinhard Marks, Heiko Becker, Justus Duyster, Ralph Wäsch, Jürgen Finke, Michael Lübbert
Journal: Blood
Blood (2023) 142 (Supplement 1): 7091.
https://doi.org/10.1182/blood-2023-187581
Published: 2023
Journal Articles

Identification of Epigenetic Modifiers Essential for Growth and Survival of AML1/ETO-Positive Leukemia

Jesus Duque Afonso, Veratti Pia, Usama-Ur Rehman, Heike Herzog, Jan Mitschke, Gabriele Greve, Julian Eble, Bettina Berberich, Johanna Thomas, Milena Pantic, Miguel Waterhouse, Gaia Gentile, Olaf Heidenreich, Cornelius Miething, Michael Lübbert
Journal: Blood
Blood (2023) 142 (Supplement 1): 5687.
https://doi.org/10.1182/blood-2023-187372
Published: 2023
Journal Articles

Decider-2: Prospective Randomized Multicenter Phase III Trial of Decitabine and Venetoclax Administered in Combination with All- Trans Retinoic Acid (ATRA) or Placebo in Patients with Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy

Michael Lübbert, Claudia Schmoor, Olga Grishina, Christoph Rummelt, Johanna Thomas, Michael Heuser, Konstanze Döhner, Hartmut Döhner, Heiko Becker, Ralph Wäsch
Journal: Blood
Blood (2023) 142 (Supplement 1): 1495.
https://doi.org/10.1182/blood-2023-181871
Published: 2023